AMRA is honoured to be participating in the FSHD International Research Congress. Register for the IRC and stop by our virtual booth for a friendly chat. To read more about whole-body MRI in FSHD Clinical Trials right away click the button below.

Recent studies highlight an important and independent relationship between sarcopenia and chronic liver diseases, particularly nonalcoholic fatty liver disease (NAFLD). Learn more from AMRA Medical Research and guest speakers from Virginia Commonwealth University and Axcella Health Inc in this webinar.

The recent development of quantitative MRI biomarkers, describing muscle atrophy and muscle fat replacement, has proven that the effect of disease activity in NMD (Neuromuscular Disorders) can be detected earlier and more precisely when compared to methods aiming at describing functional decline. Learn more in this webinar from AMRA Medical Research and guest speakers from Fulcrum Therapeutics and Pfizer.

In this free webinar we provided an introduction to body composition profiling in clinical trials – how can large scale body composition data enhance the understanding of your study participants? Request the recording and watch to tap into the discussion about recent research on the development of novel body composition phenotypes and more.

In this webinar, the featured speakers provide an introduction to Magnetic Resonance Imaging (MRI), and the MRI techniques used for body composition analysis. Request the recording and watch to learn how automatic image processing generates the measurements, see the advantages of volumetric MRI-based body and muscle composition measurements, and understand the utility of the measurements in a selection of applications and therapeutic areas.

Hepatology is the premier journal in the field of liver disease and the official journal of AASLD. AMRA is proud to be on the cover! Read about the ARRIVE trial in which AMRA’s whole-body composition analysis was used.